|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.38/-3.16
|
企业价值
297.01M
|
资产负债 |
每股账面净值
1.69
|
现金流量 |
现金流量率
--
|
损益表 |
收益
57.19M
|
每股收益
1.90
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/21 13:52 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 CTLA-4), Tebotelimab (PD-1 LAG-3), MGD024 (CD123 CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV CD3). |